Prognostic factors of liver metastases in extensive-stage small cell lung cancer receiving chemo-immunotherapy

作者：Kaira K, Kurata Y, Imai H, Shiono A, Miura Y, Hashimoto K, Yamaguchi O, Mouri A, Kagamu H · 发表于：Translational lung cancer research · 年份：2025 · DOI：10.21037/tlcr-2024-1091 · 被引用次数：32

BACKGROUND: Chemoimmunotherapy combining platinum-based chemotherapy and etoposide with an anti-programmed death-ligand 1 (PD-L1) antibody is the standard treatment for patients with extensive-stage small cell lung cancer (ES-SCLC). However, the biomarkers that can predict outcomes after chemo-immunotherapy remain unclear. This study retrospectively investigated the prognostic factors after first-line chemoimmunotherapy in patients with ES-SCLC. METHODS: This study included 110 patients with ES-SCLC who received chemoimmunotherapy as a first-line treatment. Clinical data were extracted from medical records, and inflammatory and nutritional factors such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), prognostic nutrition index (PNI), and advanced lung cancer inflammation index (ALI) were analyzed to determine the prognostic predictors. Survival data were analyzed using the log-rank test. Univariate and multivariate analyses of variables were performed using Cox regression. RESULTS: The median patient age was 72 years (range, 50-88 years). At diagnosis, metastases were present in the brain, liver, and bones in 32.7%, 25.5%, and 39.1% of cases, respectively. The platinum-based chemotherapy regimens included atezolizumab in 67.3% of cases and durvalumab in 32.8%, respectively. Univariate analysis identified sex, ALI, pro-gastrin-releasing peptide (ProGRP), liver metastasis, and bone metastasis as significant predictors of progression-free survival (...